antithrombotic regimen was maintained throughout the whole study period (median 2 years). The primary end point was defined as net clinical outcomes, a composite of major bleeding and major adverse cardiac and cerebral events (MACCE). Propensity score-matching analysis was also performed in 99 patient pairs. Results: The net clinical outcomes of the TAT group was worse than the DAPT group (34.3% v 21.1%, p¼0.006), which was mainly driven by higher incidence of major bleeding (16.7% vs 4.6%, p< 0.001), without any significant increase in MACCE (22.1% vs 17.7%, p¼0.313). In multivariate analysis, the TAT was an independent predictor for worse net clinical outcomes (HR 1.67; 95% CI 1.09-2.57; p¼0.018) and major bleeding (HR 3.74; 95% CI 1.74-8.02; p¼0.001). After propensity scorematching, TAT group still had worse net clinical outcomes, mainly driven by higher major bleeding, than DAPT group. Conclusions: In AF patients undergoing DES implantation, prolonged administration of TAT is associated with worse net clinical outcomes due to the substantial increase in major bleeding without any improvement of MACCE.
Icahn School of Medicine at Mount Sinai, New York, NY Background: Chronic kidney disease (CKD) confers increased risk for bleeding and ischemic complications after percutaneous coronary intervention (PCI). Guidelines recommend dual antiplatelet therapy (DAPT) in patients undergoing PCI and anticoagulation in patients with atrial fibrillation (AF) and CHADS2 scores!2. The optimal antithrombotic therapy in patients with CKD and AF after PCI is unknown. Methods: The AVIATOR (Antithrombotic strategy Variability In ATrial fibrillation and Obstructive coronary disease Revascularized with PCI) registry, included 859 consecutive patients with AF treated with PCI, of whom 286 had CKD (e-GFR< 60 ml/min).CKD patients were stratified in 2 groups; triple therapy (TT; warfarin plus DAPT) or DAPT (aspirin plus clopidogrel. Major adverse cardiovascular events (MACE) and clinically relevant bleeding (BARC!2) were compared between the groups at one year. Results: Mean age was similar in the 2 groups (76AE9 years). Patients receiving TT (n¼127, 44.4%) were more often male and had higher ejection fraction compared to patients discharged on DAPT (n¼159, 55.6%). Mean CHADS2 scores were identical between groups (3.1AE1). MACE incidence at 1-year was similar in the TT vs. DAPT groups (20 vs. 11%, p¼0.54) but patients on TT tended to bleed more often (15 vs. 7%, p¼0.04). However, after adjusting for confounding factors the association of TT with increased bleeding was attenuated. (Figure) Conclusions: The most commonly prescribed regimen in these high risk patients with CKD and AF undergoing PCI is DAPT. Patients on TT had similar rates of 1-year MACE but more bleeding compared to those given DAPT. Background: Elderly patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) are at an increased risk for bleeding and ischemic complications. Optimum antithrombotic therapy in this group is controversial and challenging. Methods: Among 859 patients from the AVIATOR (Antithrombotic strategy variability in AF and obstructive coronary disease) registry who underwent PCI, 387 patients with age ! 75 were selected for this analysis. At discharge, these patients were stratified into two groups: those receiving dual antiplatelet therapy (DAPT; aspirin plus clopidogrel), and those receiving triple therapy (TT; DAPT plus warfarin). Major adverse cardiovascular events (MACE) and bleeding rates in these antithrombotic groups were studied after one year. Results: The mean age of patients who received DAPT was 81AE4 years, whereas those on TT had a mean age of 80AE3 years. Patients receiving DAPT (n¼203, 52.5%) were more likely to have a history of bleeding and infarction, while those on TT (n¼184, 47.5%) had a past history of stroke. The 1-year MACE (15.7% vs 12.2%, HR 0.82, p¼0.548, for DAPT vs TT, respectively) and bleeding (9.4% vs 12.1%, HR 1.25, p¼0.413, for DAPT vs TT, respectively) rates were similar between the two groups. Conclusions: In contrast to consensus statements, elderly patients with AF undergoing PCI are most frequently treated with DAPT. Bleeding and ischemic complications remain substantial in this cohort irrespective of treatment.
TCT-478 New Oral Anticoagulants in Cancer Patients Undergoing Percutaneous Endovenous Intervention for Lower Extremity Deep Venous Thrombosis
Mohsen Sharifi Background: Development of deep venous thrombosis (DVT) in the setting of cancer portends a poor prognosis. Low molecular weight heparins ( LMWH) are considered the standard of care due to their superiority over warfarin. Additionally warfarin resistance is common in cancer patients. The subcutaneous administration of LMWH on a chronic basis is cumbersome and inconvenient. New oral anticoagulants (NOAC) are promising drugs which can simplify long term care of cancer patients with DVT. However little is known on their efficacy in this setting. We therefore sought to evaluate the role of NOAC in patients with cancer-related lower extremity (LE) DVT who received rivaroxaban and apixaban following percutaneous endovenous intervention (PEVI). Methods: PEVI was performed in 50 patients with cancer who had developed extensive symptomatic LE DVT. It was bilateral in 18 patients (36%). At the time of DVT, 15 patients (30%) were on warfarin of whom 7 had therapeutic INR (64%). PEVI was performed within 23AE5 hours of admission. All patients received heparin which was stopped after completion of PEVI. Rivaroxaban was initiated at 20 mg daily and apixaban at 5 mg twice daily, 2 hours after PEVI, and continued indefinitely.
Warfarin was stopped in all. The mean follow up was 15AE4 months. The patients were evaluated for mortality, recurrent VTE and bleeding during this period.
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